Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cigall Kadoch
Harvard Medical School, Department: None
Should you be removed from our database? Contact us at [email protected]. Read more below.
Foghorn Therapeutics
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The research project involves analyzing the role of chromatin remodeling complexes in regulating the responsiveness or resistance of tumor cells to cancer immunotherapies. Foghorn Therapeutics is discovering and developing a new major class of medicines targeting genetic mutations ion the chromatin regulatory system. The company has a broad platform based on its unique understanding of the biology of the chromatin regulatory system. The results of this research grant could further inform the development of the company’s platform.
Interrogating the role for ATP-dependent chromatin remodeling complexes in immune response
PROJECT NARRATIVE Cancer immunotherapy treatments have shown marked efficacy across a range of cancer types; however, many patients still do not respond to these treatments or initially respond but later relapse. Understanding the factors and cellular processes that impact responsiveness to immunotherapies will be essential to improving therapeutic strategies to treat patients. The investigations proposed under this F30 proposal aim to identify and mechanistically characterize epigenetic factors, specifically, ATP-dependent chromatin remodeling complexes, which modulate response to immunotherapy-based agents in efforts to define predictive biomarkers and provide the foundation for new complementary therapeutic strategies.
Filed on August 08, 2019.
Tell us what you know about Cigall Kadoch's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Cigall Kadoch”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | Value cannot be readily determined |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $0 - $4,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics, Inc. | Value cannot be readily determined |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $200,000 - $249,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $150,000 - $199,999 |
| Cigall Kadoch | Sarc | Conflict of Interest | Dana-Farber Cancer Institute | $150,000 - $199,999 |
| Cigall Kadoch | Beth Israel Deaconess Medical Center | Conflict of Interest | Foghorn Therapeutics | Value cannot be readily determined |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics, Inc. | $150,000 - $199,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $0 - $4,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.